Medicare has launched a temporary pilot program named Bridge, offering select GLP-1 weight loss medications at a fixed monthly cost of $50. This initiative aims to expand access to these treatments for eligible beneficiaries who meet strict health criteria, including documented obesity-related conditions or a BMI of 35 or higher. However, not all individuals with these conditions qualify due to additional requirements such as prior treatment attempts or specific medical documentation. The program is limited in scope and duration, focusing on evaluating the impact of reduced-cost access on patient outcomes and healthcare spending.
The pilot reflects broader efforts to address rising healthcare costs and improve affordability for high-demand prescription drugs. By testing a low-cost model, Medicare seeks to gather data on effectiveness, patient adherence, and long-term savings. While the program offers a significant reduction from typical drug prices, its reach remains constrained by eligibility rules and administrative barriers. Beneficiaries interested in participation must consult their healthcare providers to determine qualification and navigate enrollment processes.